EyePoint Pharmaceuticals
EYPT
Market cap $677M

9.84 USD

-0.01

0.10%

At close Jul 30, 4:00 PM EDT

After hours

9.99

+0.15

1.52%

1 day

-0.10%

5 days

-7.87%

1 month

4.57%

3 months

44.28%

6 months

22.24%

Year to date

22.54%

1 year

3.36%

5 years

34.79%

10 years

-75.76%

About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Employees: 144

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

22% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 46

18% more call options, than puts

Call options by funds: $1.63M | Put options by funds: $1.38M

4% more funds holding

Funds holding: 145 [Q4 2024] → 151 (+6) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

1.29% less ownership

Funds ownership: 109.06% [Q4 2024] → 107.77% (-1.29%) [Q1 2025]

27% less capital invested

Capital invested by funds: $553M [Q4 2024] → $401M (-$152M) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

124%

upside

Avg. target

$26

162%

upside

High target

$28

185%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Lisa Walter	185%upside $28	Outperform Initiated	17 Jun 2025
HC Wainwright & Co. Yi Chen	124%upside $22	Buy Reiterated	29 May 2025
Mizuho Graig Suvannavejh	164%upside $26	Outperform Maintained	16 May 2025
Chardan Capital Daniil Gataulin	174%upside $27	Buy Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about EYPT published over the past 30 days

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments.

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community –

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

Breakout Momentum Plays You May Not Know About

High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up.

Breakout Momentum Plays You May Not Know About

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference Forum: Fireside ChatDate: Tuesday, May 20, 2025Time: 10:00 a.m.

EyePoint Announces Participation at Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™